China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Novasight Hybrid System, a first-in-class intravascular dual mode imaging equipment for coronary artery imaging, has been approved for marketing in China. This marks a significant advancement in the field of cardiovascular diagnostics.
Integrating IVUS and OCT Technologies
The Novasight Hybrid System integrates two advanced imaging technologies, Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT), which can simultaneously display ultrasound and optical images within blood vessels. This dual mode imaging system provides a comprehensive view of the vascular structure, enhancing the accuracy of coronary artery imaging.
Global Recognition and Market Expansion
The Novasight Hybrid System is the first intravascular ultrasound optical dual mode imaging system approved in the US and has also obtained marketing approvals in Canada and Japan. The system’s approval in China further expands its global footprint, demonstrating its potential to improve patient outcomes in cardiovascular procedures.-Fineline Info & Tech
